🇺🇸 LGND — Ligand Pharmaceuticals Incorporated
Salud Compra fuertePrecio actual
306,20 USD
Máx. histórico
322,75
7 días
Split 1603:1000 del 02/11/2022
Caída desde máximo
-5,13%
Rango 52 semanas
175,89 – 326,63
Variación hoy
+2,41%
Cierre anterior
299,00
Rango de hoy
297,84 – 308,26
Volumen hoy
130.173
Peor caída histórica
-93,34%
06/03/2000 → 19/11/2008
Recuperado en 2694 días
Volatilidad anualizada ⓘ
59,76%
- Nombre completo
- Ligand Pharmaceuticals Incorporated
- Divisa
- USD
- Mercado
- NasdaqGM
- Sector
- Salud
- Industria
- Biotechnology
- Empleados
- 47
- PER ⓘ
- 122,97 (puede no estar actualizado)
- Dividend yield
- 0,00% (puede no estar actualizado)
- Precio objetivo analistas
- 351,33 USD (puede no estar actualizado)
- Primera cotización
- 18/11/1992
- Precio actualizado
- hace 13 horas
Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, develops and licenses biopharmaceutical assets worldwide. It offers Pradefovir, Posaconazole, Voriconazole, CAPVAXIVE, NOXAFIL, MenFive, and ZELSUVMI for infectious disease; EVOMELA and KYPROLIS for multiple myeloma; FILSPARI for the treatment of immunoglobulin a nephropathy; PNEUMOSIL, a pneumococcal conjugate vaccine to help fight against pneumococcal pneumonia in children; and QARZIBA to treat neuroblastoma. The company also provides Teriparatide injection product for osteoporosis; RYLAZE, a recombinant erwinia asparaginase for acute lymphoblastic leukemia or lymphoblastic lymphoma in adult and pediatric patients; TZIELD, a CD3-directed antibody indicated to delay the onset of Stage 3 type 1 diabetes in adults and children aged 8 years and older with Stage 2 T1D; and VAXNEUVANCE for the prevention of invasive disease caused by streptococcus pneumoniae serotypes. In addition, it offers Duavee for menopause; Frovatriptan to treat Neurology; FYCOMPA and SESQUIENT for CNS; MEKINIST for cardiology; Nexterone, a captisol-enabled formulation of amiodarone; VEKLURY, an antiviral treatment for COVID-19; and Viviant for osteoporosis. Further, the company develops ACLX-002, Ciforadenant, UGN-301, Viright, MB07133, BOT/BAL, and Lasofoxifene for oncology; Ensifentrine for respiratory disease; QTORIN for rare disease; Sparsentan for kidney disease; VK2809 for hepatology; ANEB-001 for acute cannabinoid intoxication; Reproxalap for opthamology; VK0214 for Rare Disease; and VK5211 for musculoskeletal disorder. The company was incorporated in 1987 and is based in Jupiter, Florida.
| Fecha de pago | Importe por participación |
|---|---|
| 03/04/2007 | 9,3575 USD |
| Fecha | Ratio |
|---|---|
| 02/11/2022 | 1603:1000 |
| 19/11/2010 | 1:6 |
| Fecha | Apertura | Máximo | Mínimo | Cierre | Variación | Volatilidad día | Volumen |
|---|---|---|---|---|---|---|---|
| 18/11/1992 | 48,66 | 52,40 | 44,92 | 45,85 | — | 15,38% | 886.860 |